The CANTOS study was designed as a randomized, double-blind, placebo-controlled international large-scale multicenter clinical trial enrolling 10,061 patients with a history of myocardial infarction (MI) with elevated (>2 mg/L) hypersensitivity C-reactive protein (hsCRP) from 39 countries. Here, CRP is linked to myocardial infarction.